Skip to main content
Company

Narval

We use Artificial Intelligence to design synthetic Antibody Mimetic Proteins to replace conventional antibodies in novel first-in-class therapeutics.

Mexico, North America TechCrunch Disrupt 2023

Details

Founded Date

2023

Industries
AI/Machine Learning Biotech HealthTech, Healthcare
Operating Status

Open

Currently Raising
Website

narvalbio.com/

Founders

Jose Luis Nuno Founder

News About Narval

Biotech & Health

Monoclonal antibody treatments have many challenges — Narval is fixing them

Catherine Shu

Monoclonal antibodies are the building blocks of some of the most important medical treatments in the world. But they have limitations. For example, the large size of the molecules mean monoclonal antibody treatments usually need to be injected — even for eye conditions. Narval CEO Jose Luis Nuno describes the first time he saw a […]

Startups

Introducing the 2023 Startup Battlefield Top 20 onstage at TechCrunch Disrupt

Neesha A. Tambe

I’m thrilled to announce the Startup Battlefield 20 companies, pitching at TechCrunch Disrupt 2023. After last year’s big hit, TechCrunch editorial hand-selected 200 startups, out of thousands of applicants, to comprise the Startup Battlefield 200. This year, TechCrunch saw the highest number of applications across the largest spread of countries and industries. Of the 200, […]